NCT06628349 Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
| NCT ID | NCT06628349 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Texas A&M University |
| Condition | Protein Metabolism |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-02-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal. The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal. The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.
Eligibility Criteria
Inclusion Criteria: * Age 50-95 years old * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only * Stable body-weight (±5%) for the past 3 months * Ability to walk, sit down, and stand up (independently or with walking assistance device) * Willingness to lay supine in bed for up to 6 hours * Willingness and ability to comply with the protocol Exclusion Criteria: * Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C) * History of untreated metabolic disease including hepatic or renal disorder * Presence of acute illness or metabolically unstable chronic illness * Hysterectomy * Active dependence of alcohol or drugs * Use of short course of oral corticosteroids within 4 weeks preceding study day * Current use of long-term oral corticosteroids * Use of protein or amino acids containing nutritional supplements within 5 days of the first study day * Presence of fever within the last 3 days * Planned elective surgery requiring 2 or more days of hospitalization during the entire study * (Possible) pregnancy * Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject * Already enrolled in another clinical trial * Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient * Known allergy to any of the components of the feeding (soy, pea, or whey - dairy) * Established daily diet of vegetarian / vegan composition * \<23 MoCa score
Contact & Investigator
Marielle Engelen, PhD
PRINCIPAL INVESTIGATOR
Texas A&M University
Frequently Asked Questions
Who can join the NCT06628349 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 95 Years, studying Protein Metabolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06628349 currently recruiting?
Yes, NCT06628349 is actively recruiting participants. Contact the research team at mpkj.engelen@ctral.org for enrollment information.
Where is the NCT06628349 trial being conducted?
This trial is being conducted at College Station, United States.
Who is sponsoring the NCT06628349 clinical trial?
NCT06628349 is sponsored by Texas A&M University. The principal investigator is Marielle Engelen, PhD at Texas A&M University. The trial plans to enroll 100 participants.